Test Price
2,800 AED✅ Home Collection Available
DRD4 Gene ADHD Genetic Test in UAE | 2800 AED
ISO 9001:2015 Accuracy Guarantee: 99.9% Diagnostic Sensitivity
• Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (Available daily from 8 AM to 11 PM).
• Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
• Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Executive Summary & Core Metrics
This advanced Next-Generation Sequencing (NGS) test analyses the entire coding region of the DRD4 gene to detect variants associated with attention-deficit/hyperactivity disorder (ADHD) susceptibility. Using a simple blood or DNA sample, the assay provides a comprehensive genetic risk profile to support clinical-grade diagnosis and personalised management plans in the UAE. The test is performed exclusively at our DHA-licensed facility with a turnaround time of 3 to 4 weeks.
Executive Insight from Lina Osama Zaki Quteineh, Consultant Medical Genetics: “This DRD4 NGS test offers valuable genetic insight into ADHD predisposition, yet it must always be interpreted in the context of a thorough clinical evaluation. A positive variant alone does not confirm the disorder; environmental factors and comprehensive behavioural assessment remain essential. I urge every patient to discuss these results with a qualified neurologist or psychiatrist before making any treatment decisions.”
Test Overview & Methodology
The DRD4 gene ADHD genetic test utilises Next-Generation Sequencing (NGS) to comprehensively evaluate the entire DRD4 gene coding region. This method provides superior variant detection compared to traditional PCR-based genotyping, offering full gene sequencing that identifies all known clinically relevant variants. The test is performed on whole blood, extracted DNA, or finger-prick FTA card samples collected at home or in our facility.
| Feature | Our Test – Advanced NGS | Closest Alternative (Standard Genotyping) |
|---|---|---|
| Precision | Full gene sequencing – detects all known variants | Targeted mutation panel – limited variant coverage |
| Method | Next-Generation Sequencing (NGS) | PCR-based genotyping |
| Speed | 3 to 4 Weeks | 4 to 6 Weeks |
Physician Insight & Safety Protocols
Lina Osama Zaki Quteineh | Consultant Medical Genetics | DHA Registration ID: 9294403: “This DRD4 NGS test provides a sophisticated genetic risk assessment for ADHD. However, clinical correlation remains paramount. The presence of a risk variant does not equate to a diagnosis; it must be integrated with comprehensive psychiatric and developmental evaluation. I recommend all patients pursue pre- and post-test genetic counselling to fully understand implications.”
Medication Advisory
Do not discontinue or alter any prescribed medication without consulting your physician. Genetic test results provide supplementary information to guide therapy but never replace a doctor’s clinical judgement.
Patient Safety & Exclusion Criteria
- Not recommended for individuals who refuse mandatory pre-test genetic counselling (required for minors under UAE Federal Law).
- Unsuitable if sample integrity cannot be guaranteed (e.g., severe haemolysis, recent blood transfusion).
- ER Red Flags: If the patient experiences acute neurological changes (seizures, sudden severe behavioural disturbances) before taking the test, seek emergency medical attention immediately. This genetic test is not a diagnostic tool for acute conditions.
Patient FAQ & Clinical Guidance
1. What is the DRD4 gene and its role in ADHD?
The DRD4 gene encodes the dopamine D4 receptor, and certain polymorphisms are strongly linked to attention-deficit/hyperactivity disorder (ADHD) susceptibility. These variants can affect dopamine signalling in the brain, influencing attention and impulse control. However, having a genetic variant does not guarantee the clinical manifestation of ADHD; environmental and developmental factors also play a significant role. This NGS test identifies clinically relevant DRD4 variants to aid in risk assessment.
2. How accurate is this ADHD genetic test?
With 99.9% analytical sensitivity achieved through ISO-accredited NGS technology, this test reliably detects all known pathogenic DRD4 gene variants. Clinical validity depends on the variant’s association with ADHD; our report includes an evidence-based classification. A negative result does not entirely rule out ADHD due to non-genetic causes, and a positive result must be correlated with clinical symptoms by a specialist.
3. Is the test available for children in the UAE?
Yes, the DRD4 ADHD genetic test for minors strictly follows UAE regulations, requiring informed parental consent and mandatory pre-test genetic counselling. The child’s wellbeing and data privacy are fully protected under the UAE Personal Data Protection Law (PDPL). Samples can be collected at home using a painless finger-prick FTA card, and all procedures adhere to DHA pediatric healthcare standards.
UAE Regulatory & Data Privacy Adherence
- Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL): Your genomic data is encrypted, stored locally, and never shared without explicit consent, aligning with the strictest data privacy standards.
- Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields: All digital health data handling and electronic health records comply with this law to ensure secure and ethical use of technology in healthcare.
- Federal Decree-Law No. 4 of 2016 on Medical Liability: Clinical testing safety and patient consent are governed under this law, ensuring that all genetic testing procedures are performed with full informed consent and medical accountability.
- ISO 9001:2015 Certification: Cert. INT/EGQ/2509DA/3139 – ensuring consistent quality management across sample handling, analysis, and reporting.
Clinical & Logistical Metadata
| Test Name | DRD4 Gene ADHD Genetic Test (NGS) |
| Price (AED) | 2800 AED (excluding VAT) |
| Turnaround Time | 3 to 4 weeks |
| Sample Type / Matrix | Whole blood, extracted DNA, or finger-prick FTA card (VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full gene coding region analysis |
| ICD-10-CM Code | F90.0 (ADHD, predominantly inattentive type), F90.1, F90.2, F90.8, F90.9 |
| LOINC Code | 21665-8 (DRD4 gene analysis) |
| DHA Facility License & Laboratory Address | DHA Facility License Number: 1143 Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians